SCHEMBL20786804

SCHEMBL20786804

CC(=O)Oc1cc(/C=C/c2ccc(OC(=O)CO)cc2)cc(OC(=O)CO)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 3/20 0.79
▸ MAPT P10636 3/20 0.79
▸ LMNA P02545 2/20 0.79
▸ KDM4E B2RXH2 2/20 0.79
▸ MEN1 O00255 2/20 0.79
▸ KMT2A Q03164 2/20 0.79
▸ TP53 P04637 1/20 0.79
▸ CYP3A4 P08684 1/20 0.79
▸ SMN1; SMN2 Q16637 1/20 0.79
▸ CYP19A1 P11511 2/20 0.64
▸ TUBB4A P04350 3/20 0.56
▸ TUBB P07437 3/20 0.56
▸ TUBA3C P0DPH7 3/20 0.56
▸ TUBA1B P68363 3/20 0.56
▸ TUBA4A P68366 3/20 0.56
▸ TUBB4B P68371 3/20 0.56
▸ TUBB3 Q13509 3/20 0.56
▸ TUBB2A Q13885 3/20 0.56
▸ TUBB8 Q3ZCM7 3/20 0.56
▸ TUBA3E Q6PEY2 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19165155 0.92 KMT2A (0.65) TTRMAPTLMNAKDM4EMEN1
SCHEMBL28462778 0.90 KMT2A (0.82) TTRMAPTLMNAKDM4EMEN1
Triacetylresveratrol SCHEMBL717980 0.89 TTR (1.00) TTRMAPTLMNAKDM4EMEN1
Triacetylresveratrol SCHEMBL717979 0.89 TTR (1.00) TTRMAPTLMNAKDM4EMEN1
SCHEMBL13259316 0.87 TTR (0.77) TTRMAPTLMNAKDM4EMEN1
SCHEMBL3483739 0.87 TTR (0.77) TTRMAPTLMNAKDM4EMEN1
SCHEMBL3683227 0.86 KMT2A (0.75) TTRMAPTLMNAKDM4EMEN1
SCHEMBL3687875 0.86 KMT2A (0.75) TTRMAPTLMNAKDM4EMEN1
SCHEMBL28467186 0.85 KMT2A (0.73) TTRMAPTLMNAKDM4EMEN1
SCHEMBL28467188 0.85 KMT2A (0.73) TTRMAPTLMNAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10717698-B2 Resveratrol glycolate and tartrate derivatives and synthetic methods therefor ELC MANAGEMENT LLC (US) 2020-07-21 — — US disclosed
US-20190071386-A1 RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES AND SYNTHETIC METHODS THEREFOR ELC MAN LLC (US) 2019-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10717698-B2 Resveratrol glycolate and tartrate derivatives and synthetic methods therefor GRHPR, SUCNR1, TECR TTR 1497/4885MAPT 1282/4885LMNA 3824/4885
US-20190071386-A1 RESVERATROL GLYCOLATE AND TARTRATE DERIVATIVES AND SYNTHETIC METHODS THEREFOR GRHPR, HMGCR, SUCNR1 TTR 1350/4885MAPT 970/4885LMNA 3577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback